Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-05 |
2024-09 |
-0.31 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
-0.37 |
-0.34 |
0.03 |
8.11% |
2024-05-09 |
2024-03 |
-0.45 |
-0.42 |
0.03 |
6.67% |
2024-02-28 |
2023-12 |
-0.44 |
-0.45 |
-0.01 |
-2.27% |
2023-11-07 |
2023-09 |
-0.46 |
-0.46 |
N/A |
N/A |
2023-08-08 |
2023-06 |
-0.81 |
-0.47 |
0.34 |
41.98% |
Date |
Firm |
Action |
From |
To |
2023-09-17 |
Barclays |
Upgrade |
Overweight |
Overweight |
2023-09-14 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-09-14 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-09-14 |
Stifel |
Upgrade |
Buy |
Buy |
2023-09-14 |
JMP Securities |
Upgrade |
Market Outperform |
Market Outperform |
2023-09-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-09-02 |
BELLEMIN JEAN-MARC |
Chief Financial Officer |
29.35K |
Conversion of Exercise of derivative security |
2024-09-02 |
BILINSKY IGOR P |
Chief Operating Officer |
54.42K |
Conversion of Exercise of derivative security |
2024-02-19 |
DUKES IAIN D |
Director |
54.00K |
Purchase |
2024-09-02 |
GRAF FINCKENSTEIN FRIEDRICH |
Officer |
59.34K |
Conversion of Exercise of derivative security |
2016-08-24 |
HILLSBERG SANFORD JAY |
Director |
0.00 |
Sale |
2022-05-30 |
MAYNARD RYAN D |
Director |
7.50K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
20.40M |
143.58M |
8.23% |
2023-06-29 |
Blackrock Inc. |
17.00M |
119.69M |
6.86% |
2023-06-29 |
Perceptive Advisors Llc |
14.04M |
98.82M |
5.66% |
2023-06-29 |
State Street Corporation |
13.57M |
95.50M |
5.48% |
2023-06-29 |
MHR Fund Management, LLC |
12.00M |
84.46M |
4.84% |
2023-06-29 |
Point72 Asset Management, L.P. |
7.79M |
54.82M |
3.14% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
8.87M |
53.58M |
3.58% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
6.59M |
46.39M |
2.66% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
5.21M |
36.70M |
2.10% |
2023-08-30 |
iShares Russell 2000 ETF |
4.75M |
28.67M |
1.92% |
2023-06-29 |
Vanguard Small Cap Value Index Fund |
3.61M |
25.42M |
1.46% |
2023-06-29 |
Vanguard Extended Market Index Fund |
2.80M |
19.73M |
1.13% |
Split |
Date |
0.01 : 1 |
2013-09-26 |